Efinopegdutide Guide
Hanmi
Complete guide to Efinopegdutide. Efinopegdutide is a long-acting dual GLP-1 and glucagon receptor agonist developed by Hanmi Pharmaceutical.
Hanmi\'s GLP-1/Glucagon Dual Agonist
Efinopegdutide is a long-acting dual GLP-1 and glucagon receptor agonist developed by Hanmi Pharmaceutical and partnered with MSD (Merck). Its dual mechanism targets both appetite regulation (via GLP-1) and energy expenditure (via glucagon). It has shown particular promise for reducing liver fat, positioning it as a potential treatment for MASH (metabolic dysfunction-associated steatohepatitis). Use the Shotlee app to track your current protocol and build baseline data for whatever comes next.
What Is Efinopegdutide?
Efinopegdutide is a long-acting dual GLP-1 and glucagon receptor agonist developed by Hanmi Pharmaceutical and partnered with MSD (Merck). Its dual mechanism targets both appetite regulation (via GLP-1) and energy expenditure (via glucagon). It has shown particular promise for reducing liver fat, positioning it as a potential treatment for MASH (metabolic dysfunction-associated steatohepatitis).
Track your current protocol in Shotlee while this science evolves. Having clean historical data means you can compare outcomes with precision if you ever switch medications.
How It Works
GLP-1 Agonism
Appetite suppression. Improved insulin sensitivity. Blood sugar regulation. Track metabolic data in Shotlee
Glucagon Agonism
Increases energy expenditure. Promotes liver fat breakdown. Boosts calorie burning. Monitor body comp in Shotlee
Liver Focus
Significant liver fat reduction. MASH treatment potential. Dual metabolic attack. Log all results in Shotlee
Why This Matters
By adding glucagon receptor activation to GLP-1 signaling, efinopegdutide increases energy expenditure while reducing appetite — attacking obesity from both sides. The liver fat reduction makes it esp
Clinical Data
Weight Loss (26 wks)
~9%
Liver Fat
Major ↓
Side Effects
Nausea (GI class)
Decreased appetite
Dose-dependent effects
Log symptoms in Shotlee
Vital Protocol FAQs
What is Efinopegdutide?
It is a dual GLP-1 and glucagon receptor agonist developed by Hanmi/MSD, notable for its liver fat reduction capabilities. Track your protocol in Shotlee.
Is it only for liver disease?
No, it is being studied for both obesity and MASH. The dual mechanism benefits weight loss and liver health simultaneously. Use Shotlee to monitor your progress.
Guide FAQs
Complete guide to Efinopegdutide. Efinopegdutide is a long-acting dual GLP-1 and glucagon receptor agonist developed by Hanmi Pharmaceutical.
Yes. Shotlee supports tracking Efinopegdutide doses, side effects, and health metrics. It is free to use.
References
Track Your Efinopegdutide Protocol in Shotlee
Free dose logging, side effect tracking, and health metric monitoring for your complete protocol.
🚀 Use Shotlee for Free